Please login to the form below

Not currently logged in
Email:
Password:

Allergan veteran joins Kala as head of business development

Charles McDermott has experience in ophthalmology

Kala Pharma Charles McDermott Charles McDermott, who has spent the last eight years at Allergan, has joined serious disease specialist Kala Pharmaceuticals as executive VP, business development.

McDermott was most recently VP, business development at Botox developers Allergan, and during his time at the company he completed several transaction and partnership agreements involving such products as eye inflammation treatments Acular and Acuvail, as well as Latisse to support the growth of eyelashes.

Prior to joining Allergan, McDermott spent several years at deCODE Genetics in several buinsess development positions.

He also has research experience, serving as a research scientist at Agouron Pharmaceuticals.

Kala will benefit from McDermott's experience in eye conditions as the company looks to advance its lead ophthalmic candidates towards clinical studies.

“We are rapidly gaining momentum within the ophthalmic industry and Charlie shares our vision to make a difference in the lives of patients suffering from ocular diseases,” said Dr Guillaume Pfefer, CEO of Kala.

“Based on his experience at Allergan, he fully appreciates the potential of Kala's mucosal penetrating product technology to transform clinical practice and to enable effective local treatments for serious diseases,” he added.

30th May 2013

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Four Health

Beautiful things happen when you put the right ingredients together. It’s the reason that we mix behaviour change experts with...

Latest intelligence

Enabling market access through outcomes-based pricing
Outcomes-based pricing is a potential solution to create a link between product price and real-world outcomes, while at the same time facilitating patient access to new and innovative medicines....
Five companies 20 for 2020
20 for 2020 – Five pharma companies to watch
As a new decade gets into gear, we take a look at five pharma companies that have a lot riding on 2020...
The growing clinical importance of patient-reported outcomes (PROs)
Traditionally, the success or otherwise of medical treatments has been assessed by mortality or clinical assessments of health. However, patient self-reports of health are increasingly seen as central to the...

Infographics